Stanford University
Showing 51-100 of 228 Results
-
Peter Fitzgerald, MD, PhD
Professor (Research) of Medicine (Cardiovascular), Emeritus
BioDr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering (by courtesy) at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 175 clinical trials, published over 550 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine in the past decade. In addition, he heads the Stanford/Asia MedTech innovation program.
Dr. Fitzgerald has been principle/founder of twenty-one medical device companies in the San Francisco Bay Area. He has transitioned fourteen of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2009, he co-founded TriVentures, which is an incubator/venture fund for early stage medical technology in Israel. -
Michael B. Fowler, MBBS, FRCP
Professor of Medicine (Cardiovascular), Emeritus
Current Research and Scholarly InterestsAdrenergic nervous system; beta-adrenergic function in, heart failure; drugs in heart failure.
-
Victor Froelicher, MD
Professor of Medicine (Cardiovascular) at the Veterans Affairs Palo Alto Health Care System, Emeritus
Current Research and Scholarly InterestsScreening of athletes for sudden cardiac death, Computerized ECG and clinical data management; exercise Physiology including expired gas analysis; the effect of chronic and acute exercise on the heart; digital recording of biological signals; diagnostic use of exercise testing; development of Expert Medical System software and educational tools.
-
Prasanth Ganesan
Basic Life Research Scientist, Medicine - Med/Cardiovascular Medicine
BioPrash Ganesan is a Research Scientist at Stanford Cardiovascular Medicine. His research is focused on developing novel signal processing and machine learning approaches for investigating and personalizing ablation therapy for patients with atrial fibrillation. He was previously a research fellow at the US National Institutes of Health working on conditions such as cervical cancer and Pneumonia using Deep Learning methods. He was recognized in the prestigious Forbes 30 Under 30 Asia 2022 list in Healthcare and Science category. He is a co-inventor of patents on novel mapping approaches for atrial fibrillation. He aspires to become a renowned bioengineering scientist developing innovative methods to improve healthcare globally. In his free time he enjoys hiking, playing badminton, and exploring restaurants and food places.
-
Daniel Aaron Gerber, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Gerber is a critical care cardiologist and co-director of Stanford's Cardiac ICU. He has dual subspecialty training in cardiovascular and critical care medicine and additional board certification in echocardiography. He completed his residency in internal medicine, fellowship in cardiovascular medicine, and an additional fellowship in critical care medicine at Stanford University and joined as faculty in 2021 as a Clinical Assistant Professor in the Department of Medicine’s Division of Cardiovascular Medicine.
Dr. Gerber manages the full spectrum of heart and vascular conditions with a focus on critically ill patients with life-threatening cardiovascular disease. He is active in medical education, teaching introductory echocardiography to Stanford medical students and residents, co-directing the Stanford Critical Care Medicine Critical Care Ultrasound Program, and lecturing nationally on critical care echocardiography and point-of-care ultrasonography at the Society of Critical Care Medicine’s annual congress. Finally, Dr. Gerber’s research interests focus on optimizing cardiac intensive care, including working with the Critical Care Cardiology Trials Network (CCCTN) - a national network of tertiary cardiac ICUs coordinated by the TIMI Study Group - and studying acute mechanical circulatory support techniques to improve patient outcomes and care processes. -
Joshua Gillard
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Josh Gillard is a Canadian biomedical data scientist with experience in bioinformatics, machine learning, and immunology. After completing a BSc and a MSc in Experimental Medicine at McGill university, he relocated to the Netherlands for his PhD in bioinformatics at Radboud University in Nijmegen. During his PhD, he gained experience analyzing and interpreting complex immunological data (bulk and single-cell transcriptomics, high-dimensional cytometry, high-throughput proteomics) derived from human observational or intervention studies (vaccination and experimental human infection) in order to discover molecular and cellular correlates of clinically important endpoints such as disease severity, symptom progression, and antibody responses. In 2022, Josh relocated to Stanford to join the Gaudilliere lab to develop and apply multi-omic data integration and machine learning techniques, establishing that early gestational immune dysregulation can predict preterm birth. Since 2024, in the Ashley lab, Josh is focused on applying deep learning models to investigate aberrant splicing in cardiovascular disease.
-
Diona Gjermeni
Affiliate, Med/Stanford Center for Clinical Research
Visiting Scholar, Medicine - Med/Cardiovascular MedicineBioDiona Gjermeni is a board-certified physician specialized in both Internal Medicine and Cardiology (Germany). With a strong focus on clinical research, her previous work primarily revolves around antithrombotic therapy and personalized medicine.
Currently affiliated with Stanford University, as a research fellow she is actively engaged in the Stanford Center for Clinical Research (SCCR), where he is gaining expertise in the conduct of clinical trials within the field of cardiovascular medicine. She is currently involved in a variety of clinical trials spanning multiple phases, with a particular emphasis on digital health, heart failure, and arrhythmias. Her research aims to improve patient outcomes through innovative therapies and precision medicine. Looking ahead, Dr. Gjermeni's long-term professional goal is to specialize in Electrophysiology, where she hopes to contribute further to the advancement of cardiovascular care. -
Bruna Gomes
Postdoctoral Scholar, Cardiovascular Medicine
Current Research and Scholarly InterestsThe increasing availability of very large datasets, along with recent advances in deep learning based tools for automatic extraction of cardiac traits, has led to the discovery of further common variants associated with cardiac disease. However, the genetic underpinnings of valvular heart disease remains understudied. I am interested in developing deep learning techniques to automatically extract cardiac flow information to facilitate genome-wide association studies of cardiac flow traits.
-
Francois Haddad
Clinical Professor, Medicine - Cardiovascular Medicine
BioDr. Francois Haddad, MD is a Clinical Professor of Medicine that specializes in the field of cardio-vascular imaging, pulmonary hypertension, advanced heart failure and transplantation. Dr. Haddad has over 18 years of practice in the field of cardiology. He directs Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory dedicated to translational studies in cardiovascular medicine. The laboratory focuses on (1) identifying early biomarkers of heart failure and aging, (2) bioengineering approaches to cardiovascular disease modeling and (3) novel informatic approach for the detection and risk stratification of disease. He is involved is several precision medicine initiatives in health including the Project Baseline, the Integrated Personalized Omics Profiling Initiative, the Athletic screening program at Stanford and the Strong-D cardiac rehabilitation initiative in individuals with diabetes mellitus.
-
Christiane Haeffele
Clinical Associate Professor, Medicine - Cardiovascular Medicine
Clinical Assistant Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
William Haskell
Professor (Research) of Medicine, Emeritus
Current Research and Scholarly InterestsMy major research interests and activities over the next several years will focus on the development and evaluation of the objective measurement of physical activity in free-living populations using a variety of sensing devices and mobile phones for data collection and processing. Also, I will continue to direct the Stanford Heart Network with the major mission being to assist community-based CVD prevention/treatment programs implement more effective heart attack and stroke prevention programs.
-
Paul Heidenreich, MD
Professor of Medicine (Cardiovascular)
Current Research and Scholarly InterestsMy research interests include
1) The cost-effectiveness of new cardiovascular technologies.
Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.
2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.
3) Outcomes research using existing clinical and administrative datasets.
4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction). -
Mark Hlatky, MD
Professor of Health Policy, of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.
-
Benjamin Davies Horne
Adjunct Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Benjamin Horne is an Adjunct Clinical Associate Professor who is based at the Intermountain Medical Center Heart Institute in Salt Lake City, UT, where he serves as the Director of Cardiovascular and Genetic Epidemiology. His doctoral training (PhD) in genetic epidemiology was completed at the University of Utah and he holds masters degrees in public health and in biostatistics. Dr. Horne is a fellow of the American Heart Association, a fellow of the American College of Cardiology, and a member of the American Society of Human Genetics. Dr. Horne’s research focuses on population health and precision medicine, including evaluating the genetic epidemiology of heart diseases, developing and implementing clinical decision tools for personalizing medical care, discovering the human health effects of intermittent fasting, and studying the influences of air pollution on major adverse health events.
-
Stephanie Hsiao, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Stephanie Hsiao is a clinical assistant professor at Stanford Medicine and a full-time advanced heart failure/transplant cardiologist at the Palo Alto VA. She is the associate program director of the Stanford Cardiology Fellowship and the site director of Palo Alto VA. She grew up in Taipei, Taiwan. She attended undergraduate at UC Berkeley and obtained her Master’s degree in Pharmacology at Cambridge University in the UK. She obtained her M.D. from UC San Francisco. She completed her Internal Medicine residency and General Cardiology fellowship at the California Pacific Medical Center in San Francisco, where she served as the chief resident and chief cardiology fellow. She completed her advanced heart failure/transplant cardiology fellowship at Stanford in June 2022 and joined the Stanford Faculty soon after. She has a strong interest in medical education and quality improvement. Her clinical interests include HF outreach in the VA health care systems, cardiology fellowship curriculum design/development and humanism in medicine. Her research interests include multi-organ transplantations, advanced HF therapies for the underserved and CardioPalliative integration. She plans to lead a career in medical education and quality improvement to deliver exceptional and equitable care for patients needing advanced HF therapies.
-
Hirotaka Ieki
Postdoctoral Scholar, Cardiovascular Medicine
BioCardiologist in Japan.
Research interest: precision medicine in cardiovascular disease. Genomics, Exposomics. -
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
-
Fumiaki Ikeno
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Researcher Cardiovascular Medicine, Stanford University
Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University
Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Contact Information
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406 -
Hiroyuki Inoue
Postdoctoral Scholar, Cardiovascular Medicine
BioPhysician-scientist passionate about bridging research findings and clinical practice
- Board certified cardiologist with 10+ years clinical experience, focused on cardiovascular diseases including heart failure, ischemic heart disease, arrhythmia, and general internal medicine
- Experience of 400+ cases as the primary operator in percutaneous coronary intervention, catheter ablation, and cardiac device implantation
- Research expertise in extracelluler vesicles, regenerative medicine, genome editing and gene therapy
Dr. Inoue joined the Yang lab in 2022. His research focuses on developing novel therapeutics for heart failure by targeting cardiomyocyte metabolism -
Sneha Shah Jain MD, MBA
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Sneha S. Jain is a Clinical Assistant Professor in the Division of Cardiovascular Medicine. She specializes in general cardiovascular medicine and preventive cardiology.
She received her MD from the Johns Hopkins School of Medicine and her MBA from Harvard Business School. She graduated with distinction from Duke University with a BS in Economics. She completed internal medicine resident training at Columbia/NewYork-Presbyterian, during which time she was selected as a Silverman Fellow in Healthcare Innovation. In this capacity, she worked with clinical and data science partners to build and deploy the technological infrastructure to identify patients with certain cardiac conditions earlier in the course of their disease. She subsequently pursued fellowship training in cardiovascular medicine at Stanford University prior to joining faculty.
Her research focuses on the development and responsible evaluation of AI to augment healthcare delivery and improve patient outcomes in cardiology. She works with the Stanford Center for Clinical Research and the Data Science Team at Stanford to deploy and prospectively evaluate AI solutions across the healthcare enterprise. -
Mehrnaz Nicole Jamali MD
Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. M. Nicole Jamali focus has been in leadership, scientific innovation and streamlining business ventures. Over the past 20 years since graduation from Stanford Internal Medicine Residency, she has held National Positions in AMA as Western Caucus Chair and Appointee to Joint Commission Board. She was reelected to Board of Joint Commission three terms for total of 9 years. She helped rewrite multiple TJC Standards including creation of the Stroke Center of excellence standards and annual "new ideas section of the board". At AMA she authored and passed multiple House rules on variety of subjects affecting thousands of providers and healthcare centers. Her experiences in private practice, group practice, Hospitalist, Insurance Directorship lead to multiple innovative projects including first e-prescription covering both meds and DME in 1999 titled eRemedy,. She then created the first wrong site surgery device which was patented. This project lead to creation of first Transplant App called TPOD which was then simplified to TAPP. It was beta tested in USC and perfected in UCSF Transplant.
Her work with various Insurance companies resulted in streamlined programs and teaching modules improving patient access to health care and millions of dollars in hospital savings of unnecessary admissions.
Her work in creation and streamlining and connecting with local Primary Care providers resulted in rapid expansion of the Hospitalist program of local Hospital by 300%
She is currently interested in Haptic and AI technologies in Medicine and providing 24/7 care to our veterans in remote locations or even the battlefield.
She is currently Clinical Associated Professor and the lead Hospitalist in the new Stanford Cardiovascular Hospitalist Program and enjoys the daily interaction with patients . She truly believes that her mission in life is to be at the bedside of ill patients. She treats them as one of her own family. It is not atypical for her to hand out her personal phone number to make sure they feel safe even when discharged. -
Roy Mattathu John, MD, PhD, FRCP
Clinical Professor, Medicine - Cardiovascular Medicine
BioDr. John is a fellowship-trained cardiologist with more than 25 years of experience. He is a clinical professor in the Department of Medicine at Stanford University School of Medicine.
He originally earned board certification in clinical cardiac electrophysiology in 1996 and has continued to recertify. He also has earned board certification in cardiovascular disease and internal medicine.
Dr. John diagnoses and manages all forms of cardiac arrhythmias including atrial fibrillation and ventricular arrhythmias. His special interests include catheter ablation for SVT, atrial arrhythmias, pacemaker and defibrillator implants, and lead extraction.
He has conducted extensive research. He has participated in large multi-center clinical trials, including over 30 studies as a primary investigator of drugs, devices, and ablation techniques. He helped pioneer a new way to manage scar-related ventricular tachycardia. He also helped develop innovations in cardiac pacemaker technology.
Dr. John has authored over 200 publications that include 126 original research papers. They have appeared in reputed journals such as the New England Journal of Medicine, Circulation, Lancet, Journal of the American College of Cardiology, European Heart Journal, Heart Rhythm, Journal of Cardiovascular Electrophysiology, and many more. Topics have included innovative, new techniques and technologies for the treatment of supraventricular arrhythmias, atrial fibrillation, ventricular tachycardia, catheter ablation, lead extraction, cardiac pacing, and defibrillation.
He was a member of the editorial board for Circulation and is currently on the editorial board of the publications Heart Rhythm Journal, Arrhythmia and Electrophysiology, Journal of Cardiac Electrophysiology, and Journal of Innovations in Cardiac Rhythm Management.
Dr. John also has written several chapters for medical textbooks such as Harrison’s Principles of Internal Medicine, Zipes Textbook on Cardiac Electrophysiology - Cell to Bedside, Conn’s Current Therapy, Electrical Disorders of the Heart, Cardiac Mapping, and many more.
He has made invited presentations to his peers at scientific sessions of the Heart Rhythm Society, American Heart Association, American College of Cardiology, and Heart Failure Society. He has delivered more than 60 national and international lectures. Subjects include cardiac pacing, defibrillation, heart failure, and arrhythmia management including catheter ablation for arrhythmias.
Dr. John is a fellow of the American College of Cardiology, Heart Rhythm Society, and Royal College of Physicians of London.
He has volunteered his time and expertise to provide free cardiac care to underserved patients in Bolivia, India, and Kenya. -
Neil M. Kalwani
Clinical Instructor, Medicine - Cardiovascular Medicine
BioNeil Kalwani, MD, MPP is a Clinical Instructor in the Division of Cardiovascular Medicine and Director of Preventive Cardiology at the VA Palo Alto Health Care System. He attended college at Yale University and completed graduate degrees in medicine and public policy at Harvard University. He trained in internal medicine at Brigham and Women’s Hospital before arriving at Stanford in 2018 for fellowship in cardiovascular medicine, during which he served as Chief Fellow. He then completed a postdoctoral fellowship through the Stanford-AHRQ Health Services Research Training Program in the Department of Health Policy. His clinical focus is in general and preventive cardiology and echocardiography. He practices at the VA Palo Alto Health Care System and at Stanford Health Care.
Dr. Kalwani's research focuses on the evaluation of policies and care delivery innovations designed to improve the value of care for patients with cardiovascular disease. -
Guson Kang
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Kang is an interventional cardiologist who specializes in the treatment of structural heart disease. He has expertise in complex coronary interventions, transcatheter aortic and mitral valve replacements, transcatheter mitral valve repair, left atrial appendage occlusion, PFO/septal defect closure, alcohol septal ablation, and paravalvular leak closure.
A Bay Area native, he graduated from Stanford University and obtained his medical degree at Yale University. He came back to Stanford to train in internal medicine, cardiology, and interventional cardiology before completing an advanced structural interventions fellowship at Ford Hospital. -
Michael S. Kapiloff, MD, PhD
Reinhard Family Professor, Professor (Research) of Ophthalmology and, by courtesy, of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.
URL to NCBI listing of all published works:
http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descending
For more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html -
Masataka Kawana
Assistant Professor of Medicine (Cardiovascular Medicine)
BioDr. Kawana joined the Advanced Heart Failure and Transplant Cardiology group in 2018. He completed his internal medicine, cardiovascular medicine, and heart failure training at Stanford. He also completed a postdoctoral research fellowship under Dr. James Spudich in the Department of Biochemistry. He is the Medical Director of Ambulatory Heart Failure and Cardiomyopathy Service in the Advanced Heart Failure program. He manages advanced heart failure patients in the clinic, CCU/heart failure service, and post-heart transplant/MCS service. His research interests are in the fundamental mechanism of inherited cardiomyopathies, and he studies the effect of gene mutation on the cardiac sarcomere function using cutting-edge biochemical and biophysical approaches, which would lead to the development of novel pharmacotherapy that directly modulates cardiac muscle protein. He is involved in multiple clinical trials for pharmacotherapy and novel device studies in heart failure and inherited cardiomyopathy.
-
Arash Keshavarzi
Postdoctoral Scholar, Cardiovascular Medicine
BioArash has a background in molecular biology and chemistry, and earned his PhD in AI-driven drug discovery, where his work led to the identification of three candidate drugs for breast cancer, validated both in vitro and in vivo. Following this, he joined a lab at UCSF for his first postdoctoral position which led to a patent for AI drug discovery applications which led to multiple patents and articles. Throughout his career, Arash has also been involved in multiple ventures. He served as the Chief Scientific Officer at Nucleus Genomics with $17 million seed funding, and co-founded Lumos Bio, a stealth focused on RNA-targeted drug discovery. Currently, Arash is a NIH T32 fellow postdoc in the Ashley Lab and an investment fellow in Mubadala Capital
-
Abha Khandelwal
Clinical Associate Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsCardiovascular disease in Pregnancy
Valvular Heart Disease
Cardiomyopathy
Pericardial disease
Heart Disease in South Asians
Women's Cardiovascular Disease -
Pik Fang Kho
Postdoctoral Scholar, Cardiovascular Medicine
BioI obtained my PhD in genetic epidemiology at Queensland University of Technology (Australia), where my research was focused on using genetic and genomic approaches to identify risk factors for endometrial cancer. During my graduate studies, I gained experience in large-scale genetic association studies and leveraging the correlation between diseases in genetic studies to identify novel genetic variants associated with endometrial cancer. I also developed expertise in various statistical genetic approaches in multi-omics data, including fine-mapping and colocalization analyses, to prioritize candidate causal variants and genes. I also gained extensive experience in genetic causal inference analysis to infer causality between risk factors and health outcomes.
My research focus since moving to Stanford has been the identification of genetic and non-genetic determinants of cardiometabolic diseases. I am currently involved in projects including large-scale genetic association studies, multi-trait analysis with correlated traits, development and validation of polygenic risk scores, integrative analyses with multi-omics data, as well as Mendelian randomization analyses to advance our understanding of the genetic and environmental factors that contribute to cardiometabolic diseases. -
Kiran Kaur Khush, MD
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Khush's clinical research interests include the evaluation of donors and recipients for heart transplantation; mechanisms of adverse outcomes after heart transplantation, including cardiac allograft vasculopathy and antibody-mediated rejection; and development of non-invasive diagnostic approaches for post-transplant monitoring.
-
Gloria S. Kim
Clinical Associate Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMedical education
Health services delivery
Management of chronic disease
Patient and physician satisfaction -
Juyong Brian Kim
Assistant Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsThe lifetime risk of developing cardiovascular disease (CVD) is determined by the genetic makeup and exposure to modifiable risk factors. The Cardiovascular Link to Environmental ActioN (CLEAN) Lab is interested in understanding how various environmental pollutants (eg. tobacco, e-cigarettes, air pollution and wildfire) interact with genes to affect the transcriptome, epigenome, and eventually disease phenotype of CVD. The current focus is to investigate how different toxic exposures can adversely remodel the vascular wall leading to increased cardiac events. We intersect human genomic discoveries with animal models of disease, in-vitro and in-vivo systems of exposure, single-cell sequencing technologies to solve these questions. Additionally, we collaborate with various members of the Stanford community to develop biomarkers that will aid with detection and prognosis of CVD. We are passionate about the need to reduce the environmental effects on health through strong advocacy and outreach.
(http://kimlab.stanford.edu) -
Joshua W. Knowles
Associate Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsGenetic basis of coronary disease
Genetic basis of insulin resistance
Familial Hypercholesterolemia (FH)
